Alnylam Leads Healthcare Q3 EPS Surprise Ranking With $14.01 Beat
Edgewise Therapeutics posted a $7.14 surprise and GRAIL ranked third at $4.90. Alnylam’s quarterly revenue rose 17% to $1.46 billion.

Alnylam Pharmaceuticals topped a healthcare ranking for third-quarter earnings-per-share (EPS) surprises, with its reported EPS exceeding analyst consensus by $14.01 as reporting season neared its close.
Edgewise Therapeutics ranked second with a $7.14 surprise, while GRAIL placed third at $4.90. An EPS surprise is the difference between reported earnings per share and the analyst consensus estimate; a positive amount means reported earnings were higher than expected.
The companies in the ranking span biotechnology, diagnostics, pharmaceuticals, health care services, managed care and hospital operations.
Alnylam reported $1.46 billion in third-quarter revenue, up 17% from a year earlier. Net product revenue rose 52% to $1.29 billion (Alnylam’s third-quarter results).